Related Experiment Video
Updated: Jan 1, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients
Raffaella Pippa1, Silvia Boffo2, Maria D Odero3,4,5,6
1Hematology/Oncology Program, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain.
Abstract:
Mesothelioma is an aggressive tumor that affects thousands of people every year. The therapeutic options for patients are limited; hence, a better understanding of mesothelioma biology is crucial to improve patient survival. To find new molecular targets and therapeutic strategies related to the protein phosphatase 2A (PP2A) network, we analyzed the gene expression of known PP2A inhibitors in mesothelioma patient samples. Our analysis disclosed a general overexpression of all PP2A-negative regulators in mesothelioma patients. Moreover, the expression of ANP32E and CIP2A genes, increased in 16% and 11% of cases, positively correlates with the ones of all the other PP2A regulators and the ones of the main cyclins and CDKs, suggesting the existence of a feed-forward loop that might contribute to the mesothelioma progression via PP2A inactivation. Overall, our study indicates the existence of a strategic and targetable axis between PP2A inhibitors (ANP32E and CIP2A) and cell cycle regulators (cyclin B2/CDK1) and provides a valuable rationale for using a personalized combinational therapy approach to improve mesothelioma patient survival.
Insights
This study reveals that mesothelioma tumors overexpress protein phosphatase 2A (PP2A) inhibitors, ANP32E and CIP2A. This suggests a new therapeutic strategy targeting PP2A for mesothelioma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Mesothelioma is an aggressive cancer with limited treatment options.
- Understanding mesothelioma biology is key to improving patient survival.
- Protein Phosphatase 2A (PP2A) is a critical regulator implicated in various cancers.
Purpose of the Study:
- To identify novel molecular targets and therapeutic strategies within the PP2A network in mesothelioma.
- To analyze the gene expression of PP2A inhibitors in mesothelioma patient samples.
- To investigate the correlation between PP2A regulators and cell cycle components.
Main Methods:
- Gene expression analysis of PP2A inhibitors in mesothelioma patient samples.
- Correlation analysis between PP2A regulators, cyclins, and CDKs.
- Investigated ANP32E and CIP2A gene expression patterns.
Main Results:
- Mesothelioma patients generally overexpress all PP2A-negative regulators.
- ANP32E and CIP2A gene expression increased in 16% and 11% of cases, respectively.
- Expression of ANP32E and CIP2A positively correlates with other PP2A regulators, cyclins, and CDKs, suggesting a feed-forward loop.
Conclusions:
- A feed-forward loop involving PP2A inhibitors and cell cycle regulators may drive mesothelioma progression through PP2A inactivation.
- ANP32E and CIP2A represent a targetable axis with cell cycle regulators like cyclin B2/CDK1.
- This study provides a rationale for personalized combination therapy to enhance mesothelioma patient survival.
